Connect Biopharma Holdings Limited

Healthcare · Biotechnology · United States

Last price 0.8022 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 50.52M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.